氯诺昔康治疗膝骨性关节炎的临床观察

发布时间：2018-06-25 03:44

本文选题：氯诺昔康 + 膝骨性关节炎　；参考：《中国药房》2017年05期

【摘要】：目的:考察氯诺昔康对膝骨性关节炎患者的疗效及疼痛程度的作用。方法:选择我院2014年1月-2016年1月膝骨性关节炎患者120例,按治疗方案的不同分为对照组和观察组,各60例。对照组患者给予布洛芬缓释胶囊0.3 g,bid,进行常规治疗;观察组患者在对照组基础上给予氯诺昔康8 mg,bid。两组患者均治疗4周。比较两组患者治疗前后视觉模拟(VAS)评分、临床疗效及不良反应发生情况。结果:治疗前两组患者VAS评分比较,差异无统计学意义(P0.05);治疗后,两组患者VAS评分显著降低,且观察组显著低于对照组,差异有统计学意义(P0.05)。观察组患者临床有效率为95.0%,显著高于对照组的75.0%,差异有统计学意义(P0.05)。观察组患者不良反应发生率为3.33%,显著低于对照组的11.67%,差异有统计学意义(P0.05)。结论:氯诺昔康治疗膝骨性关节炎疗效显著,能明显减轻患者疼痛程度,且安全性较好。
[Abstract]:Objective: to investigate the effect of lornoxicam on knee osteoarthritis. Methods: 120 patients with knee osteoarthritis from January 2014 to January 2016 in our hospital were divided into control group (n = 60) and observation group (n = 60). The patients in the control group were given ibuprofen sustained release capsule 0.3 g bid for routine treatment while the patients in the observation group were given lornoxicam 8 mg bid on the basis of the control group. Both groups were treated for 4 weeks. Visual analogue (VAS) scores, clinical efficacy and adverse reactions were compared between the two groups before and after treatment. Results: there was no significant difference in VAS score between the two groups before treatment (P0.05); after treatment, the VAS score of the two groups decreased significantly, and the observation group was significantly lower than the control group, the difference was statistically significant (P0.05). The clinical effective rate of the observation group was 95.0, significantly higher than that of the control group 75.0, the difference was statistically significant (P0.05). The incidence of adverse reactions in the observation group was 3.33, which was significantly lower than that in the control group (11.67). The difference was statistically significant (P0.05). Conclusion: lornoxicam is effective in the treatment of knee osteoarthritis.
【作者单位】：南阳市中心医院骨二科;
【分类号】：R684.3

【参考文献】